Front Page › Archive › April 2026
A federal investigation into the collapse of a Hartford nonprofit is raising new oversight questions that now sit uncomfortably close to Connecticut’s cannabis social equity system.
That is the date the United States government was granted U.S. Patent No. 6,630,507 for cannabinoids, formally recognizing them as compounds with medical value, including antioxidant and neuroprotective properties with potential applications in conditions such as Alzheimer’s disease, Parkinson’s disease, and stroke.
Hartford, CT — A provision in the amended version of House Bill 5350 creates a clear pathway for Social Equity cannabis businesses in Connecticut to be sold or transferred after a set period; while requiring a fixed state fee each time ownership changes.
The 2025 Medical Cannabis Caregiver Bill HB 5429 came closer than most people realize to breaking through and passing to the house.
O’Dea is pointing directly at cultivation concerns in the regulated market and acknowledging a reality policymakers rarely say out loud: the legacy market hasn’t gone anywhere, for a reason.
HARTFORD — In a stunning contradiction, Connecticut lawmakers have passed House Bill 5350 after floor debate repeatedly emphasizing that legal cannabis is “safe because it is tested” while the bill itself strips those testing standards out of state statute.
The Connecticut Department of Consumer Protection has brought a sweeping enforcement action against Rino Ferrarese and his company, Affinity Grow.
In 2025, Connecticut officials opposed expanding caregiver and patient cultivation under HB 5429 for one primary reason:
Connecticut lawmakers are advancing a cannabis amendment that quietly does something extraordinary.
A targeted bill that cuts off aerial detection programs and federal involvement in private cannabis enforcement
Three dispensary entities connected to the same business structure made coordinated payments into leadership PAC.
Connecticut has moved to classify kratom; a natural plant used by thousands of residents…as a Schedule I controlled substance, placing it in the same legal category as heroin.
